Pay in 4 interest-free payments of $6.95 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
About ACHIEVE-3 and ACHIEVE clinical trial program ACHIEVE-3 (NCT06045221) is a Phase 3, 52-week, randomized, open-label trial evaluating the efficacy and safety of orforglipron compared with oral semaglutide in adults with type 2 diabetes inadequately controlled with metformin
If you experience itching that spreads, intensifies over several hours, or accompanies other systemic symptoms, contact your healthcare provider immediately
The active ingredient L-carnitine is considered one of the top fat burners worldwide and also belongs to the most effective substances for increasing performance
Brand Name Medication Notice The following GLP-1 medications are only available through their respective manufacturers: Wegovy and Ozempic exclusively available from Novo Nordisk Mounjaro and Zepbound exclusively available from Eli Lilly and Company Affinity Whole Health is not affiliated with or endorsed by these brands, and we do not offer these medications
Slim Care prioritizes safety, custom strategies, and ongoing support, making it a smart choice if you want results that last
US$ 22.72
US$ 24.00
US$ 27.08
US$ 28.72
US$ 26.44
